• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Ekso Bionics Holdings Inc.

    3/3/25 4:30:15 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials
    Get the next $EKSO alert in real time by email
    S-8 1 ekso20250210_s8.htm FORM S-8 ekso20250210_s8.htm

     

    As filed with the U.S. Securities and Exchange Commission on March 3, 2025

     

    Registration No. 333-

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    Under

    The Securities Act of 1933

     

    Ekso Bionics Holdings, Inc.

    (Exact name of registrant as specified in its charter)

     

    Nevada

    99-0367049

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification No.)

    Ekso Bionics Holdings, Inc.

    101 Glacier Point, Suite A

    San Rafael, California, 94901

    (Address of principal executive offices, including zip code)

     

     

    Ekso Bionics 401(k) Plan

    (Full title of the plan)

     

    Scott G. Davis, Chief Executive Officer

    101 Glacier Point, Suite A

    San Rafael, California, 94901

    (510) 984-1761

    (Name, address and telephone number, including area code, of agent for service)

     

    Copies to:

     

    Mark B. Baudler

    Austin D. March

    Wilson Sonsini Goodrich & Rosati, Professional Corporation

    650 Page Mill Road

    Palo Alto, CA 94304

    (650) 493-9300

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐

    Accelerated filer ☐

    Non-accelerated filer ☒

    Smaller reporting company ☒

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ☐

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 (the “Registration Statement”) is being filed to register an additional 355,955 shares of common stock of Ekso Bionics Holdings, Inc. (the “Registrant”) to be issued pursuant to the Registrant’s Ekso Bionics 401(k) Plan (the “401(k) Plan”).

     

    This Registration Statement registers additional securities of the same class as other securities for which registration statements filed on Forms S-8 relating to shares issued to the 401(k) Plan are already effective. Pursuant to General Instruction E of Form S-8 under the Securities Act of 1933, as amended (the “Securities Act”), we incorporate by reference into this Registration Statement the contents of (a) the registration statement on Form S-8 (File No. 333-222663), filed on January 24, 2018, to the extent related to or incidental to the 401(k) Plan or the securities offered or sold under the 401(k) Plan, (b) the registration statement on Form S-8 (File No. 333-230404), filed on March 20, 2019 in its entirety, (c) the registration statement on Form S-8 (File No. 333-236412), filed on February 13, 2020 in its entirety, (d) the registration statement on Form S-8 (File No. 333-253526), filed on February 25, 2021 in its entirety, (e) the registration statement on Form S-8 (File No. 333-263035), filed on February 25, 2022 in its entirety, and (f) the registration statement on Form S-8 (File No. 333-270961), filed on March 30, 2023, in its entirety; (g) the registration statement on Form S-8 (File No. 333-278030), filed on March 18, 2024 in its entirety, and in each case excluding the exhibits to such registration statement.

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The Registrant incorporates by reference the following documents that the Registrant has previously filed with the Securities and Exchange Commission (the “Commission”):

     

     

    (a)

    The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 3, 2025 (the “Annual Report”);

     

     

    (b)

    All other reports filed pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), since the end of the fiscal year covered by the Annual Report (other than the portions of these documents not deemed to be filed); and

     

     

    (c)

    The description of the Registrant’s common stock contained in the Registrant’s Registration Statement on Form 8-A (File No. 001-37854) filed with the Commission on August 8, 2016, pursuant to Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description, including Exhibit 4.10 of the Annual Report.

     

    All reports and other documents of the Registrant or the 401(k) Plan subsequently filed with the Commission pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this Registration Statement and prior to the filing of a post-effective amendment that indicates the Registrant has sold all of the securities offered under this Registration Statement or deregisters the distribution of all such securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date that the Registrant or the 401(k) Plan, as the case may be, files such report or document; provided, however, that documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

     

     

     

    Item 8. Exhibits.

     

    Exhibit

    Number

     

    Description

    Form

    File Number

    Exhibit

    Filing Date

    4.1

     

    Restated Articles of Incorporation of the Registrant

    10-K

    001-37854

    3.1

    April 26, 2023

    4.2

     

    Amended and Restated By-Laws of the Registrant

    8-K

    001-37854

    3.2

    April 26, 2023

    4.3

     

    Form of specimen certificate

    S-3

    333-205168

    4.4

    June 23, 2015

    5.1*

     

    Opinion of Snell and Wilmer L.L.P

           

    23.1*

     

    Consent of WithumSmith+Brown, PC

           

    24.1*

     

    Power of Attorney (included in signature pages hereto).

           

    99.1

     

    The 401(k) Plan

    S-8

    333-222663

    99.1

    January 24, 2018

    107.1*

     

    Filing Fee Table

           

     

    In lieu of the opinion of counsel or determination letter contemplated by item 601(b)(5) of Regulation S-K, the Registrant hereby undertakes that it will submit or has submitted the 401(k) Plan and any amendments thereto to the Internal Revenue Service (“IRS”) in a timely manner and has made or will make all changes required by the IRS in order to qualify the 401(k) Plan.

     

     

    * Filed herewith.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Rafael, State of California, on March 3, 2025.

         

    EKSO BIONICS HOLDINGS, INC.

       

    By:

     

    /s/ Scott G. Davis

       

    Scott G. Davis

       

    Chief Executive Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Scott G. Davis and Jerome Wong, or either one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities, to sign any or all further amendments or supplements (including post-effective amendments filed pursuant to Rule 462(b) of the Securities Act of 1933, as amended) to this registration statement and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Commission, granting unto said attorney-in-fact and agent or either one of them full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully as to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact and agents, or any of them, or his substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

     

    Signatures

     

    Title

     

    Date

             

    /s/ Scott G. Davis

     

    Chief Executive Officer and Director

     

    March 3, 2025

    Scott G. Davis

      (Principal Executive Officer)    
             

    /s/ Jerome Wong

     

    Chief Financial Officer and Corporate Secretary

     

    March 3, 2025

    Jerome Wong

      (Principal Financial and Accounting Officer)    
             

    /s/ Mary Ann Cloyd

     

    Director

     

    March 3, 2025

    Mary Ann Cloyd

           
             

    /s/ Corinna Lathan

     

    Director

     

    March 3, 2025

    Corinna Lathan, Ph.D.

           
             

    /s/ Charles Li

     

    Director

     

    March 3, 2025

    Charles Li, Ph.D.

           
             

    /s/ Deborah Lafer Scher

     

    Director

     

    March 3, 2025

    Deborah Lafer Scher

           

     

     

     

     

    Ekso Bionics 401(k) Plan. Pursuant to the requirements of the Securities Act of 1933, the trustees (or other persons who administer the 401(k) Plan) have duly caused this Registration Statement to be signed on their behalf by the undersigned, thereunto duly authorized in the in the City of San Rafael, State of California, on March 3, 2025.

     

    Ekso Bionics 401(k) Plan.

       

    By:

     

    /s/ Jerome Wong

       

    Jerome Wong, on behalf of the Ekso Bionics, Inc., Plan Administrator

     

     
    Get the next $EKSO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EKSO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $EKSO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ekso Bionics Accepted into NVIDIA Connect Program

      Company unveils a strategic initiative to build the world's first known foundation model for human motion in physical rehabilitation Collaboration represents an important step toward integrating powerful new AI capabilities into Ekso Bionics' proprietary exoskeleton technology platforms SAN RAFAEL, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced its acceptance into the NVIDIA Connect program. The Company plans to use the valuable tools and resources provided through this prestigious NVIDIA program to support a new strategic

      5/15/25 7:45:00 AM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • Ekso Bionics Reports First Quarter 2025 Financial Results

      SAN RAFAEL, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended March 31, 2025. Recent Highlights and Accomplishments Strengthened financial position by improving operating cash burn by 43% combined with $3.8 million in net proceeds from the exercise of warrantsNamed National Seating & Mobility ("NSM") as its exclusive Ekso Indego® Personal device distributor within the U.S. complex rehabilitation technology ("CRT") industryNamed Bionic Prosthetics & Orthotics Group ("Bionic P&O") as its

      5/5/25 4:05:00 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • Ekso Bionics to Report First Quarter 2025 Financial Results on May 5 – Conference Call to Follow

      SAN RAFAEL, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the first quarter of 2025 after the close of trading on Monday, May 5, 2025. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to review the financial results and discuss recent business developments. To participate in the conference call by telephone, please dial 877-407-6184 (domestic) or 201-389-0877 (international). The call will also be broadcast live and archived on the Company's website at www.

      4/28/25 4:30:00 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials

    $EKSO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Lathan Corinna bought $15,477 worth of shares (13,733 units at $1.13), increasing direct ownership by 10% to 147,990 units (SEC Form 4)

      4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)

      3/14/24 6:41:52 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials

    $EKSO
    SEC Filings

    See more
    • SEC Form 10-Q filed by Ekso Bionics Holdings Inc.

      10-Q - EKSO BIONICS HOLDINGS, INC. (0001549084) (Filer)

      5/5/25 4:08:10 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • Ekso Bionics Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - EKSO BIONICS HOLDINGS, INC. (0001549084) (Filer)

      5/5/25 4:06:47 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • SEC Form 11-K filed by Ekso Bionics Holdings Inc.

      11-K - EKSO BIONICS HOLDINGS, INC. (0001549084) (Filer)

      4/18/25 4:25:35 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials

    $EKSO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Wong Jerome was granted 24,248 shares (SEC Form 4)

      4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)

      3/18/25 6:07:04 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • Chief Operating Officer Jones Jason C was granted 24,248 shares (SEC Form 4)

      4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)

      3/18/25 6:06:43 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • CEO Davis Scott G. was granted 5,590 shares (SEC Form 4)

      4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)

      3/18/25 6:06:18 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials

    $EKSO
    Leadership Updates

    Live Leadership Updates

    See more
    • Ekso Bionics Accepted into NVIDIA Connect Program

      Company unveils a strategic initiative to build the world's first known foundation model for human motion in physical rehabilitation Collaboration represents an important step toward integrating powerful new AI capabilities into Ekso Bionics' proprietary exoskeleton technology platforms SAN RAFAEL, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced its acceptance into the NVIDIA Connect program. The Company plans to use the valuable tools and resources provided through this prestigious NVIDIA program to support a new strategic

      5/15/25 7:45:00 AM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • Ekso Bionics Appoints Deborah Lafer Scher to its Board of Directors

      Brings Strategic Healthcare Expertise and Extensive Experience with the U.S. Department of Veterans Affairs (VA) to Ekso's Board Deborah Lafer Scher SAN RAFAEL, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced the appointment of Deborah Lafer Scher to its Board of Directors, effective June 6, 2024. "We are pleased to strengthen our Board with the addition of Deborah Lafer Scher, a distinguished leader who brings a wealth of healthcare experience and a proven track record of business development expertise," said Scott Davis, President and Chie

      6/17/24 4:05:00 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • Ekso Bionics Announces Acquisition of Human Motion and Control Business Unit Including Indego® Product Line From Parker Hannifin Corporation

      Broadens Ekso Bionics' product portfolio into home use Adds Vanderbilt University as a key commercial and research partner Acquisition consolidates leading lower extremity robotic companies Ekso President and COO Scott Davis promoted to Chief Executive Officer; Steven Sherman to remain Chairman, appointed Executive Chair SAN RAFAEL, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics (NASDAQ:EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced the acquisition of the Human Motion and Control ("HMC") Business Unit from Parker Hannifin Corporation ("Parker"), a global leader in motion and control technologies. The acquisiti

      12/5/22 8:37:01 AM ET
      $EKSO
      Industrial Machinery/Components
      Industrials

    $EKSO
    Financials

    Live finance-specific insights

    See more
    • Ekso Bionics Reports First Quarter 2025 Financial Results

      SAN RAFAEL, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended March 31, 2025. Recent Highlights and Accomplishments Strengthened financial position by improving operating cash burn by 43% combined with $3.8 million in net proceeds from the exercise of warrantsNamed National Seating & Mobility ("NSM") as its exclusive Ekso Indego® Personal device distributor within the U.S. complex rehabilitation technology ("CRT") industryNamed Bionic Prosthetics & Orthotics Group ("Bionic P&O") as its

      5/5/25 4:05:00 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • Ekso Bionics to Report First Quarter 2025 Financial Results on May 5 – Conference Call to Follow

      SAN RAFAEL, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the first quarter of 2025 after the close of trading on Monday, May 5, 2025. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to review the financial results and discuss recent business developments. To participate in the conference call by telephone, please dial 877-407-6184 (domestic) or 201-389-0877 (international). The call will also be broadcast live and archived on the Company's website at www.

      4/28/25 4:30:00 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • Ekso Bionics Reports Fourth Quarter and Full-Year 2024 Financial Results

      SAN RAFAEL, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and twelve months ended December 31, 2024. Recent Highlights and Accomplishments Record Q4-2024 revenue of $5.1 millionQ4-2024 gross margin increased 400 basis points year-over-year to 53%Subsequent to year-end, Company named National Seating & Mobility as its exclusive Ekso Indego® Personal device distributor within the U.S. complex rehabilitation technology (CRT) industry "We are pleased to close out 2024 with recor

      3/3/25 4:05:00 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials

    $EKSO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Ekso Bionics Holdings Inc.

      SC 13G - EKSO BIONICS HOLDINGS, INC. (0001549084) (Subject)

      11/14/24 3:29:01 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • SEC Form SC 13G/A filed by Ekso Bionics Holdings Inc. (Amendment)

      SC 13G/A - EKSO BIONICS HOLDINGS, INC. (0001549084) (Subject)

      2/11/22 6:17:59 AM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • SEC Form SC 13G filed

      SC 13G - EKSO BIONICS HOLDINGS, INC. (0001549084) (Subject)

      2/12/21 10:16:25 AM ET
      $EKSO
      Industrial Machinery/Components
      Industrials